Literature DB >> 15520487

Drug resistance in tuberculosis in India.

C N Paramasivan1, P Venkataraman.   

Abstract

The current global concern in the treatment of tuberculosis (TB) is the emergence of resistance to the two most potent drugs viz., isoniazid and rifampicin. The level of initial drug resistance is an epidemiological indicator to assess the success of the TB control programme. Though drug resistance in TB has frequently been reported from India, most of the available information is localized, sketchy or incomplete. A review of the few authentic reports indicates that there is no clear evidence of an increase in the prevalence of initial resistance over the years. However, a much higher prevalence of acquired resistance has been reported from several regions, though based on smaller numbers of patients. A strong TB control programme and continuous surveillance studies employing standardized methodology and rigorous quality control measures will serve as useful parameters in the evaluation of current treatment policies as well as the management of multidrug resistant (MDR) TB cases.

Entities:  

Mesh:

Year:  2004        PMID: 15520487

Source DB:  PubMed          Journal:  Indian J Med Res        ISSN: 0971-5916            Impact factor:   2.375


  25 in total

1.  Risk factors for MDR and XDR-TB in a tertiary referral hospital in India.

Authors:  V Balaji; Peter Daley; Alok Azad Anand; Thambu Sudarsanam; Joy Sarojini Michael; Rani Diana Sahni; Poorvi Chordia; Ige Abraham George; Kurien Thomas; Alka Ganesh; K R John; Dilip Mathai
Journal:  PLoS One       Date:  2010-03-04       Impact factor: 3.240

2.  High levels of multidrug resistant tuberculosis in new and treatment-failure patients from the Revised National Tuberculosis Control Programme in an urban metropolis (Mumbai) in Western India.

Authors:  Desiree T B D'souza; Nerges F Mistry; Tina S Vira; Yatin Dholakia; Sven Hoffner; Geoffrey Pasvol; Mark Nicol; Robert J Wilkinson
Journal:  BMC Public Health       Date:  2009-06-29       Impact factor: 3.295

3.  RNTCP and tuberculosis control - High time to act.

Authors:  Nirmal Kumar Jain
Journal:  Lung India       Date:  2010-07

4.  Prevalence of multidrug-resistant tuberculosis among newly diagnosed cases of sputum-positive pulmonary tuberculosis.

Authors:  Surendra K Sharma; Gaurav Kaushik; Brajesh Jha; Ninoo George; S K Arora; Deepak Gupta; Urvashi Singh; Mahmud Hanif; R P Vashisht
Journal:  Indian J Med Res       Date:  2011-03       Impact factor: 2.375

5.  Analysis of thyroid function tests in patients of multidrug resistance tuberculosis undergoing treatment.

Authors:  Naveen Chhabra; Neeraj Gupta; M L Aseri; Sunil K Mathur; Ramakant Dixit
Journal:  J Pharmacol Pharmacother       Date:  2011-10

6.  Ambulatory multi-drug resistant tuberculosis treatment outcomes in a cohort of HIV-infected patients in a slum setting in Mumbai, India.

Authors:  Petros Isaakidis; Helen S Cox; Bhanumati Varghese; Chiara Montaldo; Esdras Da Silva; Homa Mansoor; Joanna Ladomirska; Giovanni Sotgiu; Giovanni B Migliori; Emanuele Pontali; Peter Saranchuk; Camilla Rodrigues; Tony Reid
Journal:  PLoS One       Date:  2011-12-01       Impact factor: 3.240

7.  Drug resistance profiles of Mycobacterium tuberculosis isolates to first line anti-tuberculous drugs: A five years study.

Authors:  Sarala Menon; Sujata Dharmshale; Chhaya Chande; Aruna Gohil; Sunil Lilani; Salim Mohammad; Ameeta Joshi; Abhay Chowdhary; Renu Bharadwaj
Journal:  Lung India       Date:  2012-07

8.  Non-adherence of new pulmonary tuberculosis patients to anti-tuberculosis treatment.

Authors:  Py Kulkarni; Sv Akarte; Rm Mankeshwar; Js Bhawalkar; A Banerjee; Ad Kulkarni
Journal:  Ann Med Health Sci Res       Date:  2013-01

9.  Prevalence of multidrug resistance in Mycobacterium tuberculosis isolates from HIV seropositive and seronegative patients with pulmonary tuberculosis in north India.

Authors:  Sunil Sethi; Abhishek Mewara; Sunil Kumar Dhatwalia; Harpal Singh; Rakesh Yadav; Khushwinder Singh; Dheeraj Gupta; Ajay Wanchu; Meera Sharma
Journal:  BMC Infect Dis       Date:  2013-03-15       Impact factor: 3.090

10.  High relapse rate in RNTCP: An increasing concern and time to intervene.

Authors:  Sajal De
Journal:  Lung India       Date:  2013-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.